Probing the ligand-binding domain of the mGluR4 subtype of metabotropic glutamate receptor by Hampson, D.R. et al.
Probing the Ligand-binding Domain of the mGluR4 Subtype of
Metabotropic Glutamate Receptor*
(Received for publication, April 30, 1999, and in revised form, August 9, 1999)
David R. Hampson‡§, Xi-Ping Huang‡, Roman Pekhletski‡, Vanya Peltekova‡, Geoffrey Hornby‡,
Christian Thomsen¶, and Henning Thøgerseni
From the ‡Faculty of Pharmacy and the Department of Pharmacology, University of Toronto, Toronto, Ontario M5S 2S2,
Canada and the Departments of ¶Molecular Pharmacology and iMedicinal Chemistry, Novo Nordisk A/S,
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Metabotropic glutamate receptors (mGluRs) are
G-protein-coupled glutamate receptors that subserve a
number of diverse functions in the central nervous sys-
tem. The large extracellular amino-terminal domains
(ATDs) of mGluRs are homologous to the periplasmic
binding proteins in bacteria. In this study, a region in
the ATD of the mGluR4 subtype of mGluR postulated to
contain the ligand-binding pocket was explored by site-
directed mutagenesis using a molecular model of the
tertiary structure of the ATD as a guiding tool. Al-
though the conversion of Arg78, Ser159, or Thr182 to Ala
did not affect the level of protein expression or cell-
surface expression, all three mutations severely im-
paired the ability of the receptor to bind the agonist
L-[3H]amino-4-phosphonobutyric acid. Mutation of other
residues within or in close proximity to the proposed
binding pocket produced either no effect (Ser157 and
Ser160) or a relatively modest effect (Ser181) on ligand
affinity compared with the Arg78, Ser159, and Thr182 mu-
tations. Based on these experimental findings, together
with information obtained from the model in which the
glutamate analog L-serine O-phosphate (L-SOP) was
“docked” into the binding pocket, we suggest that the
hydroxyl groups on the side chains of Ser159 and Thr182
of mGluR4 form hydrogen bonds with the a-carboxyl
and a-amino groups on L-SOP, respectively, whereas
Arg78 forms an electrostatic interaction with the acidic
side chains of L-SOP or glutamate. The conservation of
Arg78, Ser159, and Thr182 in all members of the mGluR
family indicates that these amino acids may be funda-
mental recognition motifs for the binding of agonists to
this class of receptors.
Metabotropic glutamate receptors (mGluRs)1 are a family of
eight G-protein-coupled receptors that are expressed through-
out the central nervous system and in sensory cells of the
retina and tongue. The mGluR family has been divided into
three subgroups based on sequence homology, pharmacology,
and signal transduction properties; in cell lines, group I
mGluRs couple to phosphoinositide turnover, whereas group II
and III receptors couple to the inhibition of forskolin-stimu-
lated cAMP via Gi/Go proteins (1, 2). mGluR4 together with
mGluR6, mGluR7, and mGluR8 constitute the group III sub-
class of mGluRs that are selectively sensitive to the phosphono
derivative of L-glutamate, L-amino-4-phosphonobutyric acid (L-
AP4), and the endogenous amino acid L-serine O-phosphate
(L-SOP).
The group III mGluRs are important regulators of synaptic
transmission in the central nervous system. Electrophysiologi-
cal experiments have shown that activation of L-AP4-sensitive
receptors causes a suppression of synaptic transmission by
inhibiting neurotransmitter release from nerve terminals (3),
and immunocytochemical studies have confirmed that group
III mGluRs are localized presynaptically (4–6). The character-
ization of mutant mice lacking the mGluR4 subtype of mGluR
has provided additional insight into the function of this recep-
tor in the nervous system. For example, observations from
electrophysiological analyses demonstrating impaired presyn-
aptic functions in the mutant mice led to the suggestion that
this receptor may be required for sustaining synaptic transmis-
sion during periods of high-frequency neurotransmission (7).
Behavioral studies on mGluR4 mutant mice have shown that
this receptor plays a role in motor and spatial learning (7, 8).
The potential use of group III mGluR ligands as therapeutic
agents in epilepsy and neurodegenerative disorders has pro-
vided a persuasive argument for conducting more detailed
structural analyses of this class of neurotransmitter receptors
(9, 10).
The amino acid sequences of the mGluRs are homologous to
the periplasmic amino acid-binding proteins in bacteria (11),
the calcium-sensing receptor of the parathyroid gland (12, 13),
the GABAB receptors (14–16), a group of mammalian phero-
mone receptors (17), and a class of taste receptors expressed in
lingual tissue (18). The basic structural domains of mGluRs
include a large extracellular amino-terminal domain (ATD),
seven putative transmembrane domains, and an intracellular
carboxyl terminus. The homology of the ATDs of mGluRs to the
leucine/isoleucine/valine-binding protein (LIVBP) and other
bacterial periplasmic binding proteins that mediate the trans-
port of amino acids in prokaryotes is fortuitous because the
mGluRs appear to possess a similar three-dimensional fold and
the crystal structures of the bacterial proteins are known (11).
Data obtained from experiments on chimeric constructs of
the ATD of human mGluR4 with the transmembrane domains
and carboxyl-terminal regions of mGluR1b (19) and constructs
containing various segments of the ATD of rat mGluR2 and the
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transmembrane domain and carboxyl terminus of mGluR1a
(20) indicated that pharmacological selectivity is conferred by
residues located in the ATDs of mGluRs. More recent studies
demonstrating that the ATDs of mGluR1 (21) and mGluR4 (22)
can be expressed as soluble proteins that are secreted from
transfected cells and that retain ligand-binding capabilities
have corroborated the concept that the primary determinants
of ligand binding to mGluRs are contained within the ATDs. In
this study, we have employed molecular modeling in conjunc-
tion with site-directed mutagenesis to probe the ligand-binding
pocket of mGluR4. Our results indicate that three conserved
amino acids present in the ATDs may be key determinants of
ligand binding to all members of the mGluR family.
EXPERIMENTAL PROCEDURES
Molecular Modeling—The three-dimensional structure of the pro-
posed ligand-binding domain of rat mGluR4 was formulated by homol-
ogy modeling using the experimentally determined structure of the
closed form of LIVBP from Escherichia coli and the strategy outlined by
Blundell et al. (23). The atomic coordinates for the closed form of LIVBP
with leucine in the binding pocket were kindly provided by Dr. F. A.
Quiocho (Baylor College of Medicine). The QUANTA program (Version
97, MSI Corp.) and the SYBYL program (Version 6.4, Tripos Associates)
were used to view the model that encompassed the region from Gly47 to
Lys490 in the ATD of mGluR4. The sequence alignment used in the
mGluR4 model has been described previously (11). Backbone atom
coordinates were assigned the corresponding residue coordinates from
the crystal structure of LIVBP, and side chain atom coordinates were
based on maximal side chain atom fitting to the LIVBP structure.
Regions with insertions or deletions were modeled using known sub-
structures identified by loop-searching techniques; regions 1–46, 125–
149, 353–401, and 426–439, which are absent in LIVBP, were not
included in the model. The L-SOP molecule was docked into the binding
site of mGluR4 in an orientation that corresponds to that observed for
leucine binding to LIVBP. The model was energy-optimized using a
restrained energy minimization with additional constraints applied to
the backbone regions based on the x-ray structure of LIVBP using the
CHARMm force field. A steepest descent followed by a conjugate gra-
dient method were used for energy minimization until the energy
change per cycle was ,0.0001 kcal/mol.
Expression Vectors, Mutagenesis, and Transfections—For the expres-
sion of wild-type mGluR4a in human embryonic kidney cells (HEK-293-
TSA-201), the BglII-EcoRI fragment of mGluR4a in the pBluescript
SK2 phagemid (m4aSK2) (24) was subcloned into the pcDNA3 mam-
malian expression vector (Invitrogen, San Diego, CA) at the BamHI and
EcoRI sites. For the construction of c-Myc-tagged mGluR4a, the
mGluR4a-pcDNA3 plasmid was cut with XhoI, and the larger fragment
containing pcDNA3 backbone was ligated to itself (the 59-mGluR4a-
pcDNA3 plasmid). The primers BstEII-c-Myc (59-GT CAC GAA CAA
AAG CTT ATT TCT GAA GAA GAC TTG GAT CCA G) and rev-BstEII-
c-Myc (59-GTG ACC TGG ATC CAA GTC TTC TTC AGA AAT AAG CTT
TTG TTC) were phosphorylated, annealed to each other, and cloned into
the 59-mGluR4a-pcDNA3 plasmid at the dephosphorylated BstEII site
to produce 59-mGluR4a-c-Myc-pcDNA3. The 931-base pair NdeI-XhoI
fragment from 59-mGluR4a-c-Myc-pcDNA3 and a 3335-base pair XhoI-
NotI fragment of mGluR4a-pcDNA3 were subcloned into pcDNA3 at
NdeI-NotI sites using a three-piece ligation. The c-Myc-tagged mutants
were also constructed in this manner using the corresponding mutants.
For the generation of the S157A, S160A, and S181A mutants, the
sequences flanking the point of mutation were amplified in two sepa-
rate PCRs on the rat mGluR4a-pcDNA3 expression plasmid. For all
other mutants, the mGluR4a cDNA in pBluescript SK2 (Stratagene)
was used as the template. One of four primers used in the generation of
each mutant contained the desired mutation. An adjacent primer was
phosphorylated prior to PCR, and the two PCR products were ligated to
each other and reamplified using the two most distant primers (the
59-primer from the first PCR and the 39-primer from the second PCR).
The resulting products were cut with the appropriate restriction en-
zymes and subcloned in place of the corresponding wild-type fragment.
All expression constructs were assembled in the pcDNA3 mammalian
expression vector for transient transfection in HEK cells. In all cases,
the orientation of the inserts and the integrity of subcloning sites were
checked by restriction analysis where applicable, and the PCR-ampli-
fied regions were sequenced to confirm the mutations and to ensure
that no other changes were introduced.
A cassette mutagenesis method was used to construct the S159A
mutation. A 1.79-kilobase KpnI fragment of mGluR4a containing
Ser159 was subcloned into the pBluescript SK2 vector and transformed
into CJ236 bacteria. A mutagenic oligonucleotide (59-GGA GCT TCA
GGG GCC TCC GTC TCG ATC A-39) was annealed to the template and
used to make double-stranded mutant DNA with T4 DNA polymerase
and T4 ligase. The double-stranded mutant DNA was transformed into
DH5a cells (Life Technologies, Inc.), and rapid screening of the colonies
was carried out using the SacI restriction enzyme; the DNA from a
positive colony was sequenced to confirm the presence of the S159A
mutation and the absence of any additional base pair changes. The
mutated cassette was then excised from pBluescript SK2 and ligated
back in the correct orientation in the mGluR4a cDNA in pcDNA3.
HEK cells were cultured in modified Eagle’s medium with 6% fetal
bovine serum and antibiotics. Transient transfections were conducted
using the protocol described previously (22); all experiments were con-
ducted on cells or membranes collected 48 h after transfection.
Radioligand Binding Assay—The membrane preparation procedure
and the L-[3H]AP4 binding assay were carried out as described by
Eriksen and Thomsen (25), except that 300 mM L-SOP was used to define
nonspecific binding. Bound and free radioligands were separated by
centrifugation. For competition experiments, 30 nM L-[3H]AP4 was
used. The data were analyzed using GraphPAD Prism software.
L-[3H]AP4 (specific activity, 54 Ci/mmol), L-SOP, sodium L-glutamate,
(2S,3S,4S)-CCG/(2S,19S,29S)-2-(carboxycyclopropyl)glycine (L-CCG-1),
and (RS)-a-cyclopropyl-4-phosphonophenylglycine) (CPPG) were pur-
chased from Tocris (Bristol, United Kingdom)
Immunoblotting and Immunocytochemistry—The procedures for im-
munoblotting were carried out as described by Pickering et al. (26).
Electrophoresis samples containing 100 mM dithiothreitol were incu-
bated at 37 °C for 15 min prior to gel electrophoresis. Antibodies raised
in rabbits against the carboxyl terminus of mGluR4a were generated as
described by Risso Bradley et al. (4) and Petralia et al. (27). For immu-
nocytochemical analyses, HEK cells were washed with phosphate-buff-
ered saline (PBS) for 2 3 2 min at 48 h post-transfection and fixed with
PBS containing 4% paraformaldehyde and 4% sucrose for 10 min at
25 °C. The cells were air-dried for 15 min and then incubated in 10%
bovine serum albumin in PBS for 30 min at 25 °C. The cells were
subsequently incubated for 1 h at 25 °C with either the anti-mGluR4a
antibody or with anti-c-Myc mouse monoclonal IgG1 (Upstate Biotech-
nology, Inc.) diluted to a final concentration of 0.15 mg/ml in 3% bovine
serum albumin in PBS. The primary antibody was then removed, and
the cells were washed 5 3 5 min with PBS. After washing, the cells were
incubated for 60 min at 25 °C with biotin-conjugated anti-mouse IgG
(Sigma, B 0529) diluted to a final concentration of 2.75 mg/ml in 3%
bovine serum albumin in PBS. After incubation, the cells were washed
5 3 5 min with PBS and treated with fluorescein isothiocyanate-conju-
gated ExtrAvidin (Sigma, E 2761) diluted to a final concentration of 5
mg/ml in 3% bovine serum albumin in PBS for 60 min at 25 °C in the
dark; the cells were washed 4 3 5 min with PBS, mounted with 50%
glycerol solution in PBS, and photographed with a Zeiss Axiovert 135
TV microscope equipped with a 485-nm excitation and 530-nm emission
filter at a magnification of 3400.
Measurements of Intracellular Calcium—HEK cells were subcul-
tured onto six-wells plates 1 day before transfection at 50% confluency.
The cells were cotransfected with 4 mg of mGluR4a cDNA or mutant
cDNAs and 4 mg of Gqi9 cDNA in the pcDNA1 vector (28). At 24 h
post-transfection, the cells were plated onto 35-mm dishes (Nunc) fitted
with glass coverslips (Bellco Glass, Inc.) previously coated overnight at
37 °C with poly-L-ornithine (0.01%, Mr 40,000; Sigma) to increase ad-
hesion of the cells. At 48 h post-transfection, the cells were washed 3 3
5 min at 37 °C in wash buffer (135 mM NaCl, 5.4 mM KCl, 1.8 mM CaCl2,
0.9 mM MgCl2, and 10 mM HEPES, pH 7.4), and then loaded for 45 min
at 37 °C with 6 mM fura-2 acetoxymethyl ester (Molecular Probes, Inc.)
dissolved in wash buffer. After loading, the cells were washed 3 3 10
min with wash buffer prior to recording. Fluorescence recordings were
made on single cells using a dual excitation imaging system (Universal
Imaging Corp.) equipped with a Zeiss Axiovert 135 microscope.
RESULTS
Molecular Modeling—The ATD of mGluR4 extends from the
amino terminus to the first putative transmembrane domain
and encompasses the initial 66 kDa of the receptor protein (Fig.
1). The molecular model of the ATD of mGluR4 retains the
salient characteristics of the bacterial periplasmic binding pro-
teins. These include two domains of similar shape connected by
a hinge region made up of three interdomain crossover seg-
ments (11, 29). The large insertions at amino acids 1–46, 125–
149, 353–401, and 426–439 that were not included in the
model are all well separated from the proposed ligand-binding
site located in a cavity formed between the two domains. This
site is analogous to the leucine-binding site found in LIVBP. In
this cavity, the agonist L-SOP is held in place by hydrogen bond
interactions with both main chain and side chain atoms and
complementary ionic interactions with charged residues. With
the exception of hydrogen bonds between the ligand and the
peptide backbone of the binding domain, these interactions can
be disrupted by substituting the natural amino acids with
alanine. Thus, a series of mutations were made at selected
residues that were anticipated to interact directly with the
ligand (Arg78, Ser159, and Thr182) and at amino acids that may
be indirectly involved in binding (Ser157 and Ser181). The model
predicted that Ser160 lies outside of the binding pocket, and
therefore mutation of this residue to alanine was not likely to
affect ligand binding.
Expression of Mutant Proteins—To determine whether any of
the point mutations affected protein expression, immunoblots
of cells transiently transfected with mGluR4a or with the
R78A, S157A, S159A, S160A, S181A, or T182A mutant were
probed with an antibody raised against the carboxyl terminus
of mGluR4a. Labeled bands with relative molecular masses of
;96 and 100 kDa, which likely correspond to the non-glycosy-
lated and glycosylated forms of mGluR4, respectively, were
observed in samples of wild-type and c-Myc-tagged mGluR4a
and in all of the mutants (Fig. 2). Higher molecular mass
dimers of mGluR4 were also present as previously reported in
mouse cerebellum (7). The R78A mutant also showed an addi-
tional immunoreactive band at ;90 kDa; the nature of this
band is not known. Nevertheless, the intensity of the monomer
bands at 96 and 100 kDa was similar to that of the wild-type
receptor in all mutants including R78A, demonstrating that
none of the point mutations produced any substantial alter-
ations in the level of protein expression. The similarity in the
expression levels of wild-type mGluR4a and the S157A, S160A,
and S181A mutants was also indicated by the similar Bmax
values in the radioligand binding experiments (see below).
Pharmacological Analyses of Epitope-tagged and Mutant Re-
ceptors—Saturation analyses of L-[3H]AP4 binding to mem-
branes prepared from HEK cells transfected with the wild-type
mGluR4a expression plasmid showed a dissociation constant
(KD) and maximum number of binding sites (Bmax) of 504 nM
and 8.6 pmol/mg, respectively (Fig. 3A and Table I). The disso-
ciation constant for mGluR4a expressed in HEK cells was
similar to that reported previously for mGluR4a expressed in
hamster kidney cells (KD 5 441 nM) (25) and in insect Sf9 cells
(KD 5 480 nM) (30). A modified expression vector was also
constructed in which a c-Myc epitope tag was inserted imme-
diately downstream of the proposed signal peptide (Fig. 1). The
insertion of the c-Myc tag at this position was done (a) to
provide an extracellular antibody epitope to facilitate immuno-
cytochemical labeling (see below) and (b) to ensure that the tag
would not be cleaved by signal peptidases. c-Myc-tagged
mGluR4a displayed KD and Bmax values of 404 nM and 8.7
pmol/mg, respectively (Fig. 3B and Table I); neither value was
significantly different (p . 0.05, one-way analysis of variance
and Dunnett’s multiple comparison test) from that of the un-
tagged receptor, indicating that the insertion of the epitope at
this site did not affect ligand affinity or the level of expression
of mGluR4a.
The molecular model of the ATD of mGluR4 suggests that
Arg78, Ser159, and Thr182 interact directly with the glutamate
ligand. When mutated to alanine, all three residues produced
receptors that were nearly devoid of the ability to bind
L-[3H]AP4 (Fig. 4). The R78A, S159A, and T182A mutants
displayed 2 6 0.8, 5 6 1, and 4 6 2% (mean 6 S.E. of three
experiments) of control (wild-type mGluR4a) binding, respec-
tively. Due to the very low level of binding of the radioligand, it
was not possible to obtain estimates of affinities for these two
mutants in saturation or competition experiments. To further
probe the ligand-binding domain of mGluR4, several additional
mutations were made at amino acid residues that were pre-
dicted to be in or very near the binding pocket, but not directly
involved in ligand binding. Saturation experiments showed
that neither the dissociation constants nor the maximum num-
bers of binding sites of the S157A, S160A, and S181A mutants
were significantly different from those of the wild-type receptor
(p . 0.05, one-way analysis of variance and Dunnett’s multiple
comparison test) (Table I).
To assess the pharmacological profile of these mutants, com-
petition experiments were conducted using the agonists L-glu-
tamate, L-SOP, and L-CCG-1 and the group III antagonist
CPPG (31). The rank order of potency in the S157A, S160A, and
S181A mutants was similar to that observed in the wild-type
receptor (L-SOP . L-CCG-1 . L-glutamate . CPPG) (Fig. 5).
The inhibition constants for these drugs with the S157A and
S160A mutants were also similar to those seen with the wild-
type receptor (Table II). However, the inhibition constants for
the S181A mutant were ;3–5 times higher than those for the
wild-type receptor, indicating that this mutation produced a
moderate decrease in affinity for the series of compounds
tested.
Immunocytochemical Analysis—Although the results from
the immunoblot experiments indicated that the R78A, S159A,
and T182 mutant polypeptides were translated and expressed
at levels comparable to those of the wild-type receptor, it is
possible that the very low level of ligand binding of the mutants
was caused by misfolding and/or lack of cell-surface expression.
To investigate this possibility, an immunocytochemical analy-
sis was carried out on the c-Myc-tagged wild-type receptor, the
R78A and T182A mutant receptors, and the untagged S159A
FIG. 1. Schematic representation of the major domains of the
mGluR4 protein. The two splice variants of mGluR4 (mGluR4a and
mGluR4b) (30) that differ only in their carboxyl-terminal sequences are
indicated. The position of the segment of the ATD of mGluR4 that is
homologous to LIVBP is indicated by the open box; the black circles
within this box denote the relative positions of the point mutations
examined (R78A, S157A, S159A, S160A, S181A, and T182A). CTa,
carboxyl-terminal domain of mGluR4a; TMD, transmembrane domains
(indicated by the seven black boxes); SP, signal peptide. C-MyC indi-
cates the point of insertion of the 12-amino acid c-Myc epitope tag.
FIG. 2. Immunoblot of mock-transfected, wild-type, and mu-
tant mGluR4 receptors expressed in HEK cells. Each lane con-
tained 10 mg of protein; the blot was labeled with the antibody to the
carboxyl terminus of mGluR4a. WT, wild-type mGluR4.
receptor. Cell-surface expression was assessed by labeling
lightly fixed HEK cells (4% paraformaldehyde for 10 min) with
the anti-mGluR4a or anti-c-Myc antibody, followed by a bioti-
nylated anti-rabbit or anti-mouse secondary antibody and a
fluorescein isothiocyanate-avidin conjugate.
Cells expressing c-Myc-tagged wild-type mGluR4a labeled
with the anti-mGluR4a antibody and treated with Triton X-100
to permeabilize the cells showed intense labeling in and par-
ticularly around the periphery of the cells, whereas similarly
transfected cells not treated with Triton X-100 displayed only
background labeling (Fig. 6, A and B). The absence of specific
immunostaining in unpermeabilized transfected cells indicates
that the fixation protocol used (without Triton X-100 treat-
ment) did not cause permeabilization of the cells. The immu-
nolabeling pattern observed with the c-Myc-tagged wild-type
receptor in unpermeabilized cells labeled with the anti-c-Myc
antibody (recognizing the c-Myc epitope in the ATD of
mGluR4a; see Fig. 1) was similar to the pattern seen with the
anti-mGluR4a antibody in permeabilized cells (data not
shown). In unpermeabilized cells expressing the c-Myc-tagged
R78A mutant receptor and labeled with the anti-c-Myc anti-
body (Fig. 6C) and in Triton X-100-permeabilized cells labeled
with the anti-mGluR4a antibody (Fig. 6D), the pattern and
intensity of cell-surface labeling were similar to those seen with
the wild-type receptor. Cell-surface expression of the S159A
(Fig. 6E) and T182A (Fig. 6F) mutants was also essentially
identical to that observed with wild-type mGluR4a. Together,
the results of these experiments demonstrate that the cell-
surface expression of the R78A, S159A, and T182A mutants
was similar to that of wild-type mGluR4a.
Functional Analysis of Mutant Receptors—To establish that
the wild-type receptor and the S157A, S160A, and S181A mu-
tants expressed in HEK cells were functional receptors and to
generate EC50 values, attempts were made to measure the
inhibition of cAMP formation after stimulation by forskolin.
However, despite receptor expression and a robust forskolin-
induced increase in cAMP, the effects of glutamate and other
agonists were too weak to accurately estimate EC50 values in
this system. As an alternative qualitative assessment of recep-
tor activity, the activation of the receptors by L-glutamate was
monitored by measuring increases in intracellular calcium in
cells cotransfected with cDNAs coding for mGluRs and the
chimeric G-protein Gqi9 (28). Gomeza et al. (2) have shown that
Gi-linked mGluRs can couple to this modified G-protein and
activate phospholipase C. In the present experiments, the ac-
tivation of inositol 1,4,5-triphosphate-sensitive calcium stores
in cotransfected HEK cells was analyzed by measuring the
fluorescence induced by the binding of intracellular calcium to
fura-2. Although the magnitude of the calcium levels varied
somewhat from cell to cell and transfection to transfection, this
technique can be used to demonstrate functional coupling of
Gi-linked receptors. Most cells expressing the wild-type recep-
tor or the mutants cotransfected with Gqi9 displayed gluta-
mate-induced increases in intracellular calcium, whereas
mock-transfected cells or cells transfected with only the
mGluR4a cDNA did not respond to glutamate (Fig. 7). In two
separate experiments (transfections), the ratios of cells show-
ing a response out of the total number of cells analyzed were as
follows: mock-transfected, 0:12; mGluR4a only, 0:25; mGluR4a
1 Gqi9, 34:50; S157A 1 Gqi9, 17:24; S160A, 18:24; and S181A,
28:36.
DISCUSSION
The amino-terminal portions of the ATDs of mGluRs are
homologous to prokaryotic LIVBP, whereas two discontinuous
segments of the ionotropic glutamate receptors are homologous
to the bacterial lysine/arginine/ornithine-binding protein (11,
32, 33). Our model of the ATD of mGluR4 maintains the gen-
eral structural characteristics of the bacterial periplasmic
binding proteins. It consists of two lobes connected by a hinge
region, which, in the open configuration, forms a cleft where
the ligand can enter. After ligand binding, the cleft closes to
form a binding pocket, where the ligand is sequestered from the
surrounding solvent (Fig. 8). The amino acids mutated in this
study were all located within a region of the ATD of mGluR4
that forms part of the amino-terminal segment of the bilobed
FIG. 3. Saturation analysis of
L-[3H]AP4 binding. Membranes from
HEK cells expressing mGluR4a (A) or c-
Myc-tagged mGluR4a (B) were analyzed
in the membrane binding assay. Each ex-
periment was repeated three to four
times. Insets, Scatchard plots of the satu-
ration data. The KD and Bmax values are
summarized in Table I.
TABLE I
Affinity constants and maximal binding capacities from
L-[3H]AP4 saturation binding analyses conducted on wild-type
mGluR4a, c-Myc-tagged mGluR4a, and mutant receptors




WTa 504 6 99 8.6 6 2.9
c-Myc-WT 404 6 64 8.7 6 1.3
S157A 683 6 52 6.3 6 1.0
S160A 470 6 72 5.0 6 1.6
S181A 570 6 52 4.2 6 1.2
a Wild-type.
FIG. 4. Comparison of L-[3H]AP4 binding to membranes pre-
pared from HEK cells expressing wild-type mGluR4a and the
R78A, S159A, and T182A mGluR4a mutants. L-[3H]AP4 binding was
conducted at 30 nM L-[3H]AP4. Each bar represents the mean 6 S.E. of
five experiments. WT, wild-type mGluR4a.
“clamshell” part of the ATD. The rationale for targeting se-
lected amino acids for mutagenesis was guided by the model of
the ATD of mGluR4, which is, in turn, based on the known
three-dimensional structure of LIVBP determined by x-ray dif-
fraction studies (29).
Based on the sequence homology and structural data from
crystallographic studies on the bacterial amino acid-binding
proteins, O’Hara et al. (11) formulated and tested a molecular
model of the ATD of the group I receptor, mGluR1. Mutation of
either Ser165 or Thr188 in the ATD of mGluR1 caused substan-
tial reductions in the agonist-evoked stimulation of phosphati-
dylinositol hydrolysis and in the binding of L-[3H]glutamate,
suggesting that these amino acids may be involved in ligand
recognition. Ser165 and Thr188 of mGluR1 align with Ser159 and
Thr182 of mGluR4 (see Fig. 9B for a compilation of equivalent
residues mutated in mGluR1, mGluR4, GABAB receptors, and
LIVBP). Although the amino acid sequence of rat mGluR4 is
only 43% identical to that of rat mGluR1 and the two receptors
display different pharmacological and biochemical profiles, our
results indicate that at least three conserved amino acids in the
ATDs of mGluRs may be key determinants of ligand binding to
all members of the mGluR family.
In the molecular model of the ATD of mGluR4, mutations at
Arg78, Ser159, and Thr182 were predicted to have a major impact
on L-[3H]AP4 binding, whereas mutations at Ser157, Ser160, and
Ser181 were predicted to have less dramatic effects on binding;
our experimental results have corroborated the predictions of
the molecular model of mGluR4. The substantial reductions in
L-[3H]AP4 binding in the R78A, S159A, and T182A mutants
suggest that these amino acids are directly involved in ligand
recognition. It is unlikely that the large decrease in binding
was caused by a reduction in protein expression and/or mis-
folding of the mutant receptors because immunoblot and im-
munocytochemical analyses demonstrated that both mutants
were expressed at similar levels and showed similar cell-sur-
face expression patterns compared with the wild-type receptor.
The drastic reduction in L-[3H]AP4 binding in the S159A
mutant agrees with the loss of activity seen in the analogous
mutation in mGluR1 (Ser165) (11). Our molecular model sug-
gests that the hydroxyl group on the side chain of this serine
forms a hydrogen bond with the a-carboxylic acid group on the
glutamate ligand (Fig. 8). The nearly complete loss of
L-[3H]AP4 binding in the Arg78 mutant indicates that this
amino acid is another crucial feature of the ligand recognition
motif in mGluR4. Although no equivalent mutation has been
made in other mGluRs, this arginine is also conserved in all
mGluRs, and it is well positioned for such an interaction. The
orientation of the ligand in the binding pocket places the g-car-
boxy group on the side chain of L-glutamate in close proximity
to the positive charge on the side chain of Arg78 (Fig. 8). We
postulate that an ion pair between the g-carboxyl group on the
side chain of L-glutamate or the g-phosphonate group on L-SOP
or L-AP4 and the amino group on the side chain of Arg78 is an
essential component of the ligand-binding pocket of mGluRs.
This suggestion is supported by the fact that this arginine is
conserved in all members of the mammalian mGluR family, the
salmon brain mGluR, and the Drosophila mGluR, but not in
the bacterial binding proteins such as LIVBP that mediate the
transport of amino acids lacking an acidic side chain.
Mutation of Thr182 to alanine in mGluR4 produced a 96%
decrease in L-[3H]AP4 binding compared with the wild-type
receptor. In mGluR1a, conversion of the analogous threonine
(Thr188) to alanine virtually eliminated [3H]glutamate binding
(11). The threonine at position 182 of mGluR4 is conserved in
18 homologous proteins, including all eight members of the
mammalian mGluR family, an mGluR1 homolog from salmon
brain, an mGluR from Drosophila, the calcium-sensing recep-
tor, the GBR2 GABAB receptor subunit, LIVBPs and the
leucine-binding proteins from E. coli and Salmonella typhi-
murium, and an amide-binding protein (AmiC) from Pseudo-
monas aeruginosa. AmiC has been subclassified with LIVBP
and the leucine-binding proteins in “cluster 4” of the bacterial
periplasmic binding proteins (34). As is the case with other
periplasmic binding proteins, AmiC has low sequence identity
to LIVBP (17%), but the overall fold of the protein appears to be
FIG. 5. Radioligand binding compe-
tition experiments with wild-type
mGluR4a and the S157A, S160A, and
S181A mutants. All experiments were
carried out using 30 nM L-[3H]AP4. Each
point represents the average of three ex-
periments; error bars depict S.E. The in-
hibition constants are listed in Table II.
WT, wild-type mGluR4a.
TABLE II
Inhibition constants of various drugs for L-[3H]AP4 binding to wild-
type mGluR4a and the S157A, S160A, and S181A mutants




L-SOP L-CCG-1 L-Glutamate CPPG
mM
Wild-type 2.7 6 0.5 4.0 6 1.5 5.7 6 0.5 24 6 2.7
S157A 2.2 6 0.5 2.3 6 0.6 11 6 3.6 10.3 6 4.3
S160A 3.2 6 0.5 3.8 6 0.3 4.0 6 2.6 21.3 6 1.1
S181A 10 6 2 16 6 4.1 29 6 5.3 69 6 13
similar to that of LIVBP and other members of this subclass of
binding proteins (35). Thus, based on these experimental find-
ings, the molecular model of mGluR4, and the high degree of
amino acid conservation in the related proteins noted above, we
suggest that ligand binding in mGluRs is stabilized by a hy-
drogen bond formed between the oxygen of the hydroxyl group
on the side chain of Thr182 and the a-amino group of the ligand
(Fig. 8).
In light of the sequence homology between the mGluRs and
the GABAB receptors and the fact that both classes of receptors
are activated by amino acids, it is conceivable that some of the
determinants of ligand binding to mGluRs may extend to the
GABAB receptor. A sequence alignment of the mGluRs with the
GABAB receptor subunits shows that Ser
159 of mGluR4 is con-
served in GBR1a/b, whereas Thr182 of mGluR4 is conserved in
the GBR2 protein; in the GBR1a and GBR1b subunits, there is
a serine at this position (Fig. 9).
Galvez et al. (37) have examined several sites in the GBR1a
protein using site-directed mutagenesis; the amino acids mu-
tated included Ser246 and Ser269, which align with Ser159 and
Thr182, respectively, of mGluR4. Mutation of Ser246 completely
eliminated antagonist binding to GBR1a. Thus, this serine
residue appears to be critical for ligand binding to both mGluRs
and GABAB receptors. Analogous to mGluRs, Ser
246 of
GBR1a/b may form a hydrogen bond with the amino group of
GABA. Mutation of Ser269 to alanine in GBR1a caused a re-
duction in affinities for various GABAB receptor ligands; these
changes in affinity ranged from a 5- to 50-fold decrease in
affinity depending on the ligand. Based on the relatively mod-
est effects on binding, Galvez et al. (37) suggested that Ser269 of
GBR1a was likely not directly involved in ligand binding to the
GABAB receptor. However, the threonine at the equivalent
position of the GBR2 subunit (Fig. 9A) has not yet been as-
sessed in mutagenesis studies and this subunit is obligatory for
reconstituting wild-type pharmacology (15, 16). Additional mu-
tagenesis experiments on the ligand-binding site of hetero-
meric GABAB receptors may help to clarify both the similari-
ties and the unique characteristics of the binding domains
within the mGluRs and the GABAB receptors.
In addition to R78A, S159A, and T182A, several additional
mutations were made at amino acids that are positioned within
or near the ligand-binding pocket. Ser181 may be located in
close proximity to Ser159. As noted above, the hydroxyl groups
on the side chains of Ser159 of mGluR4 and Ser165 of mGluR1
may form hydrogen bonds with the a-carboxyl group of the
ligand. The position of the hydroxyl group on the side chain of
Ser181 close to the side chain of Ser159 of mGluR4 suggests the
possibility that the precise positioning of Ser159 might be de-
pendent upon hydrogen bonding between the side chains of the
two amino acids. The data from the competition experiments,
in which mutation of Ser181 to alanine resulted in an ;4-fold
increase in the IC50 values for the series of drugs tested, sup-
port this idea and indicate that Ser181 may be indirectly in-
volved in ligand binding through the formation of a hydrogen
bond with Ser159.
The model of the ATD indicates that Ser160 is situated just
outside the binding cavity and is not likely to be involved in
ligand recognition, whereas Ser157 could be indirectly involved
in ligand recognition due to hydrogen bonding to Arg78. In both
cases, mutation to alanine produced no discernible effects on
L-[3H]AP4 binding. These results indicate that Ser160 is likely
located outside of the ligand-binding pocket and that if a hy-
drogen bond between Ser157 and Arg78 does exist, it is not
critical for ligand binding. Ser160 of mGluR4 is conserved in all
other members of the mGluR family except mGluR2, which has
FIG. 6. Fluorescence immunostaining of transfected HEK
cells. Cells expressing c-Myc-tagged mGluR4a and treated (A) or not
(B) with Triton X-100 to permeabilize the cells were labeled with the
anti-mGluR4a antibody. Cells expressing c-Myc-tagged R78A without
permeabilization and labeled with the anti-c-Myc antibody (C) and
c-Myc-tagged R78A-expressing cells permeabilized with Triton X-100
and immunolabeled with the anti-mGluR4a antibody (D) showed cell-
surface expression similar to that seen with the wild-type receptor.
Permeabilized cells expressing the untagged S159A mutant receptor
and labeled with the anti-mGluR4a antibody (E) and unpermeabilized
cells expressing the c-Myc-tagged T182A mutant and labeled with the
anti-c-Myc antibody (F) also displayed cell-surface expression as ob-
served with the wild-type receptor. FIG. 7. Representative recordings of intracellular calcium re-
lease from HEK cells cotransfected with mGluRs and Gqi9. A,
mGluR4a only; B, untransfected cells; C, mGluR4a 1 Gqi9; D, S157A 1
Gqi9; E, S160A 1 Gqi9; F, S181A 1 Gqi9. The cells were loaded with
fura-2 acetoxymethyl ester and washed with recording buffer prior to
the addition of glutamate (1 mM final concentration) at 0.5–0.75 min
after initiation of recording.
an aspartate in this position. Interestingly, Kubo et al. (36)
have reported that mGluR1, mGluR3, and mGluR5 are acti-
vated by millimolar concentrations of extracellular calcium in
the absence of L-glutamate and that the serine residues at this
position (equivalent to Ser160 of mGluR4) in wild-type mGluR1,
mGluR3, and mGluR5 are required for activation by calcium.
Mutation of the aspartate in mGluR2 to serine confers calcium
sensitivity to mGluR2, whereas conversion of the analogous
serines in mGluR1, mGluR3, and mGluR5 to aspartates reduces
calcium sensitivity. Consistent with our observation that the
S160A mutation in mGluR4 did not affect ligand binding, the
mutations affecting calcium activation in mGluR1, mGluR3, and
mGluR5 did not affect the EC50 values for glutamate activation of
mGluR1, mGluR3, and mGluR5 expressed in oocytes (36).
The endogenous ligand for mGluRs is generally assumed to
be L-glutamate. However, other amino acids that are present in
brain tissue may also act as activators of mGluRs. Although
L-AP4 does not exist in the brain, L-SOP is present in micro-
molar concentrations in the mammalian central nervous sys-
tem (38). The possibility that substances other than L-gluta-
mate may act as endogenous ligands for mGluRs has been
supported by recent findings indicating that the neuropeptide
N-acetylaspartylglutamate may be a selective ligand for the
mGluR3 subtype of mGluR (39). Our data indicating that
mGluR4 has an ;2–3-fold higher affinity for L-SOP compared
with L-glutamate suggest that L-SOP could act as an endoge-
nous ligand for mGluR4 and other group III mGluRs. The
higher affinity of L-SOP for mGluR4 compared with L-gluta-
mate together with the relative selectivity of L-SOP for group
III mGluRs suggest that this subclass of mGluRs might be
preferentially activated by L-SOP over L-glutamate in vivo.
Future modeling and mutagenesis studies will likely provide
more detailed insight into the molecular basis of the selective
activation of group III mGluRs by phosphate-containing amino
acids such as L-AP4 and L-SOP.
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